anti-CD30 CAR T cells / Wuhan Bio–Raid - LARVOL DELTA

Autologous stem cell transplantation in tandem with Anti-CD30 CAR T-cell infusion in relapsed/refractory CD30 lymphoma. (PubMed, Exp Hematol Oncol) - "Our work demonstrates the combined administration of ASCT and CAR30 T-cell therapy is well-tolerate and highly effective in r/r cHL and ALCL, even in PET-positive or chemorefractory patients who are expected to have inferior outcome after ASCT, although further large-scaled validation in prospective clinical trial is warranted. Trial registration The trial was registered with the Chinese Clinical Trial Registry (ChiCTR, number ChiCTR2100053662)."

CAR T-Cell Therapy • Journal • Bone Marrow Transplantation • Hematological Malignancies • Hodgkin Lymphoma • Inflammation • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • Transplantation • ALK

Camrelizumab Combined With CD30 CAR-T in the Treatment of Relapsed/Refractory CD30+ Lymphoma (clinicaltrials.gov) - P2 | N=30 | Recruiting | Sponsor: Huazhong University of Science and Technology

New P2 trial • Hematological Malignancies • Lymphoma • Oncology • TNFRSF8